AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...
24/7 Wall St on MSN17h
George Soros $4 Billion Hedge Fund Can't Stop Buying These 3 StocksBillionaire investor George Soros became nearly a household name in the early 1990’s by shorting the British pound and making ...
The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.
Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback